209917-92-0

Basic information

• Product Name: 2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE
• Synonyms: AKOS BH-0178;2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE;2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-AMINE;2'-(Trifluoromethyl)-biphenyl-4-amine
• CAS NO: 209917-92-0
• Molecular Formula: C₁₃H₁₀F₃N
• Molecular Weight: 237.22
• Mol File: 209917-92-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE(209917-92-0)
• EPA Substance Registry System: 2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE(209917-92-0)

Safety Data

• Hazardous Substances Data: 209917-92-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2'-Trifluoromethyl-biphenyl-4-ylamine serves as a key intermediate in organic synthesis, facilitating the creation of a variety of complex organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2'-trifluoromethyl-biphenyl-4-ylamine is utilized as a building block for the development of new drugs, potentially leading to advancements in medicinal chemistry.
Used in Agrochemical Industry:
2'-TRIFLUOROMETHYL-BIPHENYL-4-YLAMINE also finds application in the agrochemical industry, where it may be employed in the synthesis of novel agrochemicals to improve crop protection and yield.
As a Building Block for Other Organic Compounds:
2'-Trifluoromethyl-biphenyl-4-ylamine's unique structure allows it to act as a versatile building block, enabling the synthesis of a wide range of organic compounds for various applications across different industries.

Upstream product

• 1423-27-4 2-(trifluoromethyl)phenylboronic acid 
• 106-40-1 4-bromo-aniline 

Relevant articles and documents

Novel 5-methyl-2-phenylphenanthridium derivatives as FtsZ-targeting antibacterial agents from structural simplification of natural product sanguinarine

A novel series of 5-methyl-2-phenylphenanthridium derivatives were displayed outstanding activity against a panel of antibiotic-sensitive and -resistant bacteria strains compared with their precursor sanguinarine, ciprofloxacin and oxacillin sodium. Compounds 7 l, 7m and 7n were found to display the most effective activity against five sensitive strains (0.06–2 μg/mL) and three resistant strains (0.25–4 μg/mL). The kinetic profiles indicated that compound 7l possessed the strongest bactericidal effect on S. aureus ATCC25923, with the MBC value of 16 μg/mL. The cell morphology and the FtsZ polymerization assays indicated that these compounds inhibited the bacterial proliferation by interfering the function of bacterial FtsZ. The SARs showed that all the 4-methyl-substituted 5-methyl-2-phenylphenanthridium subseries could be further investigated as the FtsZ-targeting antibacterial agents.

NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

NOVEL HETEROCYCLIC AMIDE DERIVATIVES HAVING DIHYDROOROTATE DEHYDROGENASE INHIBITING ACTIVITY

Novel heterocyclic amide derivatives having pharmacological effects, that is, compounds represented by the general formula (1) or salts thereof: (1) wherein X1-X2 is S-CH2 or the like; R1 is alkyl or the like; p is 0 to 7; R2 is hydrogen, alkyl, or the like; R3 is hydrogen, alkyl, or the like; Y1-Y2 is CH=CH or the like; R4 is halogeno, alkyl, or the like; q is 0 to 4; and R5 is halogeno, hydrogen, alkyl, or the like.

CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN

Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar?1?, Ar?2?, R?1?, R?2?, n and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in th

OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1

Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly re